| |
New research provides more
evidence to back green teaÍs anti-cancer effects in humans.
The teaÍs active agent Epigallocatecin-3-gallate, already
thought to lower cholesterol, prevent heart disease, fight
bacteria and dental cavities, and possibly aid weight loss,
may also slow tumour growth in breast and liver cancers,
suggests research presented this week.
|
| |
31/10/2003
"Laboratory
studies have suggested that green tea consumption may produce
many health benefits, including
the prevention of cancer, but the beneficial effects in humans
are not clearly known," said Dr CS Yang from Rutgers University,
N.J at this weekÍs Frontiers in Cancer Prevention Research
meeting in the US.
"Research is now showing how this novel
chemopreventive agent might work at the molecular level and
in the human population," he added.
Green tea polyphenols (GTP),
highly effective agents in inhibiting a variety of cancer-induced
tumours in different models, may be valuable in preventing
and helping the early detection of liver cancer, suggested
researchers from the Texas Tech University System. The team
reported on recent research showing how GTP reduced the risk
factors represented by two biomarkers for liver cancer, aflatoxin
markers and urinary excretion of 8-hydroxydeoxyguanosine (8-OHdG).
The study involved 124 people aged 20 to 55, who tested positive
for both hepatitis-B surface antigen and aflatoxin-albumin
adducts. Aflatoxin is a naturally occurring poisonous substance
produced by mold that can be found in blood serum, plasma or
urine (albumin). They were randomly divided into three groups
and treated daily with either low-dose GTP (500 mg), high-dose
GTP (1,000 mg) or placebo for three months.
In the first arm
of the study, urine samples were collected at day 0, one month
and three months to assess urinary 8-OHdG and GTP biomarkers.
After one month, EGC had increased 1.7-fold in both treated
groups. EC increased 2.2-fold in the low-dose group and 3.5-fold
in the high-dose group. Samples collected at three months showed
similar patterns.
Levels of 8-OHdG at baseline were comparable
for all three groups and did not show obvious changes at one
month. But at three months, 8-OHdG was greatly reduced in GTP-treated
groups, as compared to that in the placebo group. The results
suggest that urinary EGC and EC are good biomarkers for GTP
intake, and GTP treatment reduces urinary excretion of 8-OHdG.
In the second arm of the study, blood and urine samples were
collected at day 0, one month and three months to assess AF
(aflatoxin) biomarkers. Levels of AF-albumin adduct at baseline
were comparable for all three groups. Sample levels collected
at one month were significantly decreased in the high-dose
group, as compared with the placebo group. At three months,
the levels of AF-albumin adduct were significantly decreased
in the low-dose and high-dose groups, as compared with the
baseline levels.
"These results demonstrate that green tea
polyphenol treatment effectively inhibits phase I enzyme activities
and enhances the phase II enzyme activities," said Dr Jia-Sheng
Wang, lead investigator of the study.
"At the same time, we
see the value of green tea polyphenols in reducing excretion
of 8-OHdG. All of this is good news for the prevention and
early detection of liver cancer," he added.
Further research
on green tea revealed at the meeting describes the methods
to produce analogs for epigallocatchin-3-gallate (EGCG), the
most abundant and active chemopreventive agent in green tea.
Although associated with reduced risk of breast, pancreatic,
colon, esophageal and lung cancers in humans, EGCGÍs low oral
bioavailability means that individuals would need drink at
least seven to eight cups of tea a day, or ingest large amounts
of green tea polyphenol extract, to see any benefits.
Researchers
from California-based SRI International have successfully synthesised
several EGCG analogs that inhibit the in vitro growth of tumour
cell lines with potencies equal to or greater than EGCG itself.
The investigators developed a chemical synthesis of cis racemic
EGCG that allows them to modify the A-, B- and D-rings of EGCG
independently of each other. Using this method, they created
several different analogs (a chemical compound structurally
similar, but different in composition).
SR 13196, an analog
modified in the B- and D-rings, displays significantly more
potent growth inhibition of breast cancer cell lines when compared
to EGCG. SR 13193, an analog modified in the D-ring, inhibits
expression of the potent angiogenic factor VEGF (vascular endothelial
growth factor) in breast cancer cells, similar to EGCG.
"These
analogs are not only valuable tools to clarify how green tea
may fight cancer, but are also potential chemopreventive drug
candidates themselves, with perhaps better pharmacokinetic
properties than have been seen with EGCG thus far," said SRI's
Dr Nurulain Zaveri, lead author of the study.
Researchers from
the Arizona Cancer Center in Tucson also discussed their study showing
how green tea can help prevent the DNA damage caused by smoking.
The research was recently presented at the Third International
Scientific Symposium on Tea and Human Health.
While scientists
continue to research how green tea can prevent human disease,
the continuing stream of good news linked to the beverage has
led food makers to include green tea flavours and extracts
in a growing number of foods.
Copyright © 2000/2003
NOVIS
BeverageDaily.com
|